Huahai Pharmaceutical announced that the holding subsidiary of the company, Shanghai Huaotai Biopharmaceutical Co., Ltd., plans to implement a capital increase and share expansion and introduce external investors such as Yangtze River Delta Venture Capital Guidance Fund partnerships. Investors in this round plan to invest no more than 350 million yuan in cash. It is expected that the share ratio of Huaotai will not exceed 5.9829% after obtaining the capital increase. After the capital increase was completed, the company held no less than 81.8643% of Huaotai's shares, and Huaotai was still included in the scope of the company's consolidated statements. This transaction does not constitute a related transaction or major asset restructuring. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review. As of the disclosure date of the announcement, the relevant capital increase agreement had not yet been signed, the full list of investors in this round had not yet been finalized, and there was uncertainty about the implementation of the deal.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.